Merck to Acquire Themis – Merck

Sourced from Merck Press Release

KENILWORTH, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Themis, a company focused on vaccines and immune-modulation therapies for infectious diseases and cancer, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire privately-held Themis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200526005237/en/

Themis has a broad pipeline of vaccine candidates and immune-modulatory therapies developed using its innovative measles virus vector platform based on a vector originally developed by scientists at the Institut Pasteur, a world-leading European vaccine research institute, and licensed exclusively to Themis for select viral indications. In March, Themis joined a consortium together with the Institut Pasteur and The Center for Vaccine Research at the University of Pittsburgh, supported by funding from the Coalition for Epidemic Preparedness Innovations (CEPI), to develop a vaccine candidate targeting SARS-CoV-2 for the prevention of COVID-19.

Read more here.

By Jessica Yap-Chung
Jessica Yap-Chung Profile Picture